Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Upgraded at Zacks Research

Zacks Research upgraded shares of Swedish Orphan Biovitrum (OTCMKTS:BIOVF – Free Report) from a hold rating to a strong-buy rating in a research note published on Thursday,Zacks reports.

A number of other research analysts have also issued reports on BIOVF. HC Wainwright restated a “buy” rating on shares of Swedish Orphan Biovitrum in a research note on Wednesday, October 28th. Pareto Securities upgraded shares of Swedish Orphan Biovitrum from a “hold” rating to a “buy” rating in a research note on Tuesday, October 27th. Finally, Nordea Equity Research lowered shares of Swedish Orphan Biovitrum to a “hold” rating in a report on Thursday, October 22nd. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, Swedish Orphan Biovitrum currently has a consensus rating of “Moderate Buy”.

Read Our Latest Analysis on Swedish Orphan Biovitrum

Swedish Orphan Biovitrum Stock Performance

Shares of Swedish Orphan Biovitrum stock opened at $51.05 on Thursday. The firm has a market capitalization of $18.17 billion, a P/E ratio of 23.42 and a beta of 0.48. The company has a quick ratio of 0.55, a current ratio of 0.88 and a debt-to-equity ratio of 0.20. The company has a 50 day moving average price of $46.40 and a 200 day moving average price of $45.13. Swedish Orphan Biovitrum has a 52 week low of $35.25 and a 52 week high of $51.05.

Swedish Orphan Biovitrum Company Profile

(Get Free Report)

Swedish Orphan Biovitrum AB, known as Sobi, is a Swedish biopharmaceutical company focused on developing and providing treatments for rare and other serious diseases. Its work centers on hematology, immunology and specialized medicines for conditions with limited treatment options. Sobi’s portfolio includes therapies for blood disorders such as hemophilia, as well as treatments for rare inflammatory and immune-related conditions. The company also develops and commercializes medicines for other rare diseases, working with research and commercial partners where appropriate.

Read More

Analyst Recommendations for Swedish Orphan Biovitrum (OTCMKTS:BIOVF)

Receive News & Ratings for Swedish Orphan Biovitrum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Biovitrum and related companies with MarketBeat.com's FREE daily email newsletter.